Heloisa P. Soares

7.2k total citations · 2 hit papers
100 papers, 3.4k citations indexed

About

Heloisa P. Soares is a scholar working on Oncology, Epidemiology and Neurology. According to data from OpenAlex, Heloisa P. Soares has authored 100 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Oncology, 30 papers in Epidemiology and 17 papers in Neurology. Recurrent topics in Heloisa P. Soares's work include Neuroendocrine Tumor Research Advances (29 papers), Lung Cancer Research Studies (24 papers) and Pancreatic and Hepatic Oncology Research (18 papers). Heloisa P. Soares is often cited by papers focused on Neuroendocrine Tumor Research Advances (29 papers), Lung Cancer Research Studies (24 papers) and Pancreatic and Hepatic Oncology Research (18 papers). Heloisa P. Soares collaborates with scholars based in United States, Canada and Brazil. Heloisa P. Soares's co-authors include Benjamin Djulbegović, Enrique Rozengurt, Ambuj Kumar, Caio Rocha‐Lima, Rakesh Singal, Luis E. Raez, Auro del Giglio, R. Edward Coleman, Barry A. Siegel and Lawrence H. Einhorn and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Heloisa P. Soares

95 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Recommendations on the Use of ¹⁸F-FDG PET in Oncology

2008 790 citations James Fletcher, Benjamin Djulbegović et al. profile →
Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline

2019 285 citations Rachna T. Shroff, Heloisa P. Soares et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Heloisa P. Soares United States	25	1.2k	775	720	682	652	100	3.4k
Claire L. Vale United Kingdom	25	996 0.8×	1.3k 1.7×	2.2k 3.0×	358 0.5×	508 0.8×	56	4.4k
Elvira C van Dalen Netherlands	38	1.5k 1.2×	942 1.2×	277 0.4×	355 0.5×	726 1.1×	121	5.3k
Irene Terrenato Italy	31	561 0.5×	360 0.5×	520 0.7×	238 0.3×	692 1.1×	135	3.2k
Lynda Wyld United Kingdom	31	1.5k 1.2×	684 0.9×	554 0.8×	405 0.6×	449 0.7×	149	3.8k
Sjoerd G. Elias Netherlands	43	1.7k 1.4×	1.0k 1.3×	677 0.9×	800 1.2×	617 0.9×	159	4.9k
Adedayo A. Onitilo United States	28	1.7k 1.4×	619 0.8×	533 0.7×	360 0.5×	775 1.2×	167	3.7k
L. Douglas Case United States	36	1.9k 1.6×	1.0k 1.3×	682 0.9×	196 0.3×	409 0.6×	105	4.4k
Jean Latreille Canada	30	1.7k 1.4×	558 0.7×	1.0k 1.4×	220 0.3×	435 0.7×	89	3.7k
Marc Botteman United States	36	1.2k 1.0×	899 1.2×	1.3k 1.8×	290 0.4×	711 1.1×	212	5.5k
Rui Qin United States	33	2.3k 1.9×	941 1.2×	1.0k 1.4×	144 0.2×	524 0.8×	139	4.2k

Countries citing papers authored by Heloisa P. Soares

Since Specialization

Citations

This map shows the geographic impact of Heloisa P. Soares's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heloisa P. Soares with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heloisa P. Soares more than expected).

Fields of papers citing papers by Heloisa P. Soares

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heloisa P. Soares. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heloisa P. Soares. The network helps show where Heloisa P. Soares may publish in the future.

Co-authorship network of co-authors of Heloisa P. Soares

This figure shows the co-authorship network connecting the top 25 collaborators of Heloisa P. Soares. A scholar is included among the top collaborators of Heloisa P. Soares based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heloisa P. Soares. Heloisa P. Soares is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lozada, John R., Andrew Elliott, Mark G. Evans, et al.. (2025). Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting. Cancer Research Communications. 5(2). 318–326. 2 indexed citations

Shaw, Matthew, et al.. (2025). KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma. JAMA Network Open. 8(1). e2453588–e2453588. 8 indexed citations

Altemani, Albina, et al.. (2024). Potential role of the Eph/ephrin system in colorectal cancer: emerging druggable molecular targets. Frontiers in Oncology. 14. 1275330–1275330. 2 indexed citations

Wainberg, Zev A., Yongjun Cha, Jasmaninder Singh Grewal, et al.. (2024). 659P Combination treatment with TTX-030, a first-in-class anti-CD39 antibody, in patients with advanced pancreatic cancer. Annals of Oncology. 35. S519–S520. 3 indexed citations

Kamboj, Mini, Kari Bohlke, Kieron Dunleavy, et al.. (2024). Vaccination of Adults With Cancer: ASCO Guideline. Journal of Clinical Oncology. 42(14). 1699–1721. 36 indexed citations

Soares, Heloisa P., et al.. (2024). Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations. Hepatology. 82(5). 1287–1302. 3 indexed citations

McPherson, Jordan P., Magdalena Kovacsovics-Bankowski, Joanne Jeter, et al.. (2023). A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome. Frontiers in Immunology. 14. 1229823–1229823. 16 indexed citations

Hope, Thomas A., Samuel A. Mehr, Michael J. Morris, et al.. (2023). ACTION-1: A Randomized Phase Ib/3 trial of RYZ101 Compared with SoC in SSTR2+ Well-Differentiated GEP-NET with Progression Following Lu-177 SSA. Endocrine Abstracts. 1 indexed citations

Florou, Vaia, Charalampos S. Floudas, Asaf Maoz, et al.. (2023). Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden. Journal for ImmunoTherapy of Cancer. 11(8). e007440–e007440. 9 indexed citations

10.

Florou, Vaia, Andrew Elliott, Matthew H. Bailey, et al.. (2023). Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC. Clinical Cancer Research. 29(17). 3408–3417. 10 indexed citations

11.

Soares, Heloisa P., et al.. (2023). Case report: Efficacy of lutetium-177 oxodotreotide for neuroendocrine tumor with central nervous system metastases. PubMed. 3. 1074948–1074948. 2 indexed citations

12.

Sahai, Vaibhav, Kent A. Griffith, Bruce Lin, et al.. (2022). A multicenter phase Ib/II study of liposomal-irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) with nivolumab as second-line therapy for patients with advanced biliary tract cancer (BilT-03).. Journal of Clinical Oncology. 40(4_suppl). 438–438. 2 indexed citations

13.

Parsons, Maddy, Shane Lloyd, Skyler B. Johnson, et al.. (2022). The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients. Journal of Gastrointestinal Cancer. 54(2). 492–500. 4 indexed citations

14.

Kim, Richard D., Hanna K. Sanoff, Andrew Poklepovic, et al.. (2020). A multi‐institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer. Cancer. 126(15). 3464–3470. 34 indexed citations

15.

Soares, Heloisa P., et al.. (2015). Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2. Molecular Cancer Therapeutics. 14(4). 1014–1023. 81 indexed citations

16.

Fletcher, James, Benjamin Djulbegović, Heloisa P. Soares, et al.. (2014). Recommendations on the Use of 18F-FDG PET in Oncology.

17.

Sinnett‐Smith, James, Jia Wang, Heloisa P. Soares, et al.. (2014). Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells. PLoS ONE. 9(12). e114573–e114573. 62 indexed citations

18.

Trufelli, Damila Cristina, et al.. (2008). Burnout in cancer professionals: a systematic review and meta-analysis. European Journal of Cancer Care. 17(6). 524–31. 165 indexed citations

19.

Kumar, Ambuj, Heloisa P. Soares, & Benjamin Djulbegović. (2005). Are Statistically Non-Significant Findings Necessarily Negative? A Review of All Phase III Randomized Controlled Trials in Hematology Conducted by NCI Sponsored Cooperative Groups.. Blood. 106(11). 293–293. 1 indexed citations

20.

Fonseca, Fernando Luiz Affonso, et al.. (2002). Peripheral Blood c-erbB-2 Expression by Reverse Transcriptase—Polymerase Chain Reaction in Breast Cancer Patients Receiving Chemotherapy. Clinical Breast Cancer. 3(3). 201–205. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact